BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, April 30, 2012
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
4/27
cls
|
|
Alexion
Pharmaceuticals Inc. (NASDAQ:ALXN)
|
Brean
Murray
|
Jonathan
Aschoff
|
Price
target
|
Buy
|
-1%
|
$90.56
|
|
|
Jefferies
|
Eun
Yang
|
Price
target
|
Hold
|
|
|
|
|
ThinkEquity
|
Marko
Kozul
|
Price
target
|
Buy
|
|
|
|
Aschoff
raised his target to $105 from $85 after Alexion reported 1Q12 EPS and
revenues that beat the consensus estimates (see EPS Watch, A16).
The biotech raised 2012 revenue guidance to $1.07-$1.08B from $1.04-$1.07B
and non-GAAP EPS guidance to $1.65-$1.75 from $1.60-$1.70 Aschoff expects
Alexion to be at the upper end of the new revenue guidance range and "would
not be at all surprised" if it beat. Alexion markets Soliris eculizumab
to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic
uremic syndrome (aHUS); both the rare blood disorders.
|
|
Yang
raised her target to $76 from $68 on earnings.
|
|
Kozul
raised his target to $95 from $90 on earnings.
|
|
Incyte
Corp. (NASDAQ:INCY)
|
Brean
Murray
|
Jonathan
Aschoff
|
Price
target
|
Buy
|
18%
|
$22.94
|
|
Aschoff
raised his target to $28 from $23 after Incyte reported 1Q12 sales for
myelofibrosis drug Jakafi ruxolitinib of $19.3M, beating his estimate of
about $10M. Aschoff now projects $163M in Jakafi sales for 2012, noting that
launch surveys show that doctors are "pleased with the rapid symptom
improvement of patients" on the drug. Novartis AG (NYSE:NVS;
SIX:NOVN) has exclusive ex-U.S. rights to Jakafi, which is under review in
Europe.
|
224
words displayed of
861
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]